Scott Braunstein's most recent trade in ATAI Life Sciences N.V. was a trade of 103,000 Stock Option done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ATAI Life Sciences N.V. | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 103,000 | 103,000 | - | - | Stock Option | |
| RAPT Therapeutics Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Caribou Biosciences Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 40,500 | 40,500 | - | - | Option to purchase Common Stock | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 1.13 per share. | 05 Aug 2024 | 12,145 | 298,667 (0%) | 0% | 1.1 | 13,724 | Common Stock |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 167,825 | 167,825 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2024 | 37,300 | 310,812 (0%) | 0% | 0 | Common Stock | |
| ATAI Life Sciences N.V. | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 206,000 | 206,000 | - | - | Stock Option | |
| Trevena Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 13,700 | 13,700 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Mar 2024 | 50,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.28 per share. | 27 Mar 2024 | 50,000 | 273,512 (0%) | 0% | 4.3 | 214,000 | Common Stock |
| Caribou Biosciences Inc | Braunstein Scott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 39,500 | 39,500 | - | - | Option to purchase Common Stock | |
| Marinus Pharmaceuticals Inc | Braunstein Scott | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 9.94 per share. | 16 Feb 2024 | 11,850 | 223,512 (0%) | 0% | 9.9 | 117,789 | Common Stock |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 335,650 | 335,650 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2024 | 74,600 | 235,362 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 9.55 per share. | 07 Aug 2023 | 6,413 | 160,792 (0%) | 0% | 9.5 | 61,244 | Common Stock |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Sale of securities on an exchange or to another person at price $ 8.93 per share. | 07 Aug 2023 | 30 | 160,762 (0%) | 0% | 8.9 | 268 | Common Stock |
| Trevena Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 13,700 | 13,700 | - | - | Stock Option (Right to Buy) | |
| Caribou Biosciences Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 21,500 | 21,500 | - | - | Option to purchase Common Stock | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 360,000 | 360,000 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, CHAIRMAN AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 80,000 | 167,205 (0%) | 0% | 0 | Common Stock | |
| Trevena Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 19,305 | 87,205 (0%) | 0% | 0 | Common Stock | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 193,050 | 193,050 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 42,900 | 67,900 (0%) | 0% | 0 | Common Stock | |
| Caribou Biosciences Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2021 | 27,500 | 27,500 | - | - | Option to purchase Common Stock | |
| Trevena Inc | Scott Braunstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 68,577 | 68,577 | - | - | Stock Option (Right to Buy) | |
| Marinus Pharmaceuticals Inc | Scott Braunstein | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 290,000 | 290,000 | - | - | Stock option (right to buy) |